Yanan Zhang ^1* Ruoyu Meng ² Dan Sha ² Huiquan Gao ³ Shengxi Wang ^2* Jun Zhou ^2* Xiaoshan Wang ^1* Fuxia Li ^2* Xinyu Li ^2* Wei Song ^2*

• ¹ Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
• ² Shandong Provincial Hospital, Jinan, China
• ³ Yantai Yuhuangding Hospital, Yantai, Shandong Province, China

Colorectal cancer (CRC) ranks among the most prevalent gastrointestinal tumors globally and poses a significant threat to human health. In recent years, tumor organoids have emerged as ideal models for clinical disease research owing to their ability to closely mimic the original tumor tissue and maintain a stable phenotypic structure. Organoid technology has found widespread application in basic tumor research, precision therapy, and new drug development, establishing itself as a reliable preclinical model in CRC research. This has significantly advanced individualized and precise tumor therapies. Additionally, the integration of single-cell technology has enhanced the precision of organoid studies, offering deeper insights into tumor heterogeneity and treatment response, thereby contributing to the development of personalized treatment approaches. This review outlines the evolution of colorectal cancer organoid technology and highlights its strengths in modeling colorectal malignancies. This review also summarizes the progress made in precision tumor medicine and addresses the challenges in organoid research, particularly when organoid research is combined with single-cell technology. Furthermore, this review explores the future potential of organoid technology in the standardization of culture techniques, high-throughput screening applications, and single-cell multi-omics integration, offering novel directions for future colorectal cancer research.